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Letters to the Editor 
Pituitary Gland  Metastases 
To the Editor: 
The article by Sioutos et al (1) provides important in- 
formation on the symptoms caused by pituitary gland me- 
tastases. I draw your attention to an old publication de- 
scribing another interesting effect of pituitary gland me- 
tastases. 
In a Dutch journal in 1965 (2) I described three patients 
with breast carcinoma who manifested diabetes insipidus 
during the course of their disseminated breast cancer and 
showed after the onset of the diabetes insipidus a striking 
improvement in disability from the metastases. These im- 
provements could not be attributed to medical treatment. 
All three patients were in the terminal stages of metastatic 
carcinoma (skin metastases, regional metastases, pleuri- 
tis carcinomatosa, and bone metastases). The patients 
were 43, 53, and 55 years of age. In the youngest patient, 
the course before spontaneous remission was so rapidly 
progressive that hormonal therapy was not attempted. 
The 53-year-old patient had had a remission of 6 months 
on ovariectomy and prednisone therapy; and the 55-year- 
old patient had had a brief remission after androgen treat- 
ment. The disease again became progressive in these two 
patients before the appearance of signs of diabetes insip- 
idus. None of the patients had been treated with cytotoxic 
drugs. Spontaneous improvement in the symptoms, re- 
calcification of osteolytic foci, regression of cutataeous 
and lymph node metastases, and disappearance of  the 
carcinoma pleuritis began shortly after the onset of the 
diabetes insipidus. In two cases, the rate of tumor growth 
was thought to be rapid, and spontaneous remission was 
of relatively short duration (6 months). In contrast, re- 
mission in the oldest patient lasted for 2 years. In all three 
cases, there was an associated diabetes insipidus that re- 
sponded favorably to Piton sniff. In one patient, the dia- 
betes insipidus slowly disappeared. In two patients, ra- 
diologic examination showed distinct destruction of the 
sella turcica area. Various functional tests confirmed hy- 
pofunction of the pituitary. In one patient autopsy was 
performed, which showed that the pituitary had a normal 
aspect but was invaded entirely by tumor tissue. 
This peculiar phenomenon of "therapeutic" impact of  
the pituitary gland metastases in hormone-dependent tu- 
mors was not mentioned in the otherwise important arti- 
cle of Sioutos et al. 
J. A. van Dongen 
The Netherlands Cancer Institute 
Amsterdam, The Netherlands 
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Multi-institutional Melanoma Vaccine Trial 
To the Editor: 
In the article by Wallack et al. (1), the authors conclude 
that subset analysis of a randomized phase III vaccine 
trial "shows encouraging survival benefits in certain sub- 
sets of patients and an increasing trend in overall sur- 
vival." The authors go on to state in their discussion that 
"the subset of patients with clinical stage I, pathologic 
stage II disease had a definite survival advantage on 
VMO when compared with V" and that "male patients 
who are <57 years of age and who have one to five pos- 
itive nodes had improved survival on VMO."  They state 
uncategorically that "even though these results are not 
statistically significant, they are both interesting and com- 
pelling." 
This characterization of the results of these subset anal- 
yses is simply unfounded. These results are most defi- 
nitely not compelling, as the conclusions made in this 
article are not justified by the data presented. The authors 
have violated fundamental principles governing the anal- 
ysis of treatment effects in subgroups of patients in ran- 
domized clinical trials. These principles have been enu- 
merated by Yusuf et al. (2). The most fundamental flaw is 
the use of data-derived subgroups, which were not incor- 
porated into the design of the trial. The selection of males 
<57 years of age with one to five positive nodes has no 
biologic, clinical, or scientific rationale whatsoever. It 
was evidently chosen only because it gave the lowest 
possible p value the authors could find. Even with this 
unjustified subgroup analysis, the result did not achieve 
statistical significance. From a statistical standpoint, 
none of the appropriate statistical comparisons for this 
type of trial (such as global tests for interactions among 
pre-defined subsets) are presented, nor is there any indi- 
cation of whether or not p values were adjusted for the 
multiple comparisons that must have been performed be- 
fore the subgroup of males <57 years of  age with one to 
five positive nodes was finally discovered to be nearly but 
not quite significant. 
It is possible that active, specific immunotherapy will 
one day be shown to have a beneficial role in the treat- 
ment of patients with resected malignant melanoma. That 
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day will only come when properly conducted randomized 
trials show an overall improvement in disease-free sur- 
vival and survival that is statistically significant. This trial 
did not do so. 
Vernon K. Sondak, MD 
Associate Professor of Surgery 
University of Michigan Medical Center 
Ann Arbor, Michigan 
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A u t h o r s '  Rep ly  
To the Editor: 
We thank Dr. Sondak for his review of our article. 
This study was the first ever randomized prospective 
double bl ind Melanoma Vaccinia  Oncolysate  (VMO) 
Vaccine trial that was both FDA and NCI approved and 
funded. Bias was eliminated by making the placebo (vac- 
cinia vaccine virus) resemble the VMO so that neither the 
patient nor the doctor  knew which treatment was being 
given. Furthermore,  the vaccine distribution center and 
the trial biostatistical center were located at an institution 
far removed from the principal investigator 's  institution 
to further eliminate investigator bias. We believed the 
trial was well organized and designed and we hope that it 
will serve others as a strong model for organizing and 
performing future cancer  vaccine trials.  Thus,  even 
though the results of the first interim analysis were not 
statistically significant in showing either an improvement 
in disease-free interval or  survival, we did believe that by 
performing a retrospective analysis of  the data, we could 
find some interesting hypothesis in the subsets that we 
could use as a base for designing future melanoma vac- 
cine trials. We certainly stated this rationale very clearly 
in the articles that we have written on this trial, and we 
never claimed statistical significance. As a result of this 
decision, subsets of all male patients >57 years old with 
one to five positive nodes, and subsets of patients who 
had clinical Stage I and pathological Stage II disease were 
identified as showing a higher survival rate with VMO 
than with V. The survival curve of these subsets exhib- 
ited a trend in survival in favor of  the VMO therapy which 
perhaps could be important for future vaccine trial de- 
signs and could demonstrate that perhaps melanoma vac- 
cines could act differently on patients at the same stage, 
depending upon age and sex. Moreover,  we do recognize 
that the multiple testing issues and the p values for these 
subset analyses have little value, as the trial was not de- 
signed prospectively with enough patients to test vaccine 
efficacy in these subsets. However ,  again, we do state 
that the reason for doing this analysis is to perhaps alert 
future investigators that they may want to design random- 
ized prospective melanoma trials with more subsets. Fur- 
thermore, [in an article published in the Journal of the 
American College of  Surgeons, September 19, 1995, Vol. 
181, 193-201] Barth et al. (1) clearly review the various 
characteristics of approximately 1,521 stage IV mela- 
noma patients in their data base and show that when one 
begins to consider prognostic factors in melanoma, it may 
be important to consider age and sex as well as tumor 
location and depth of invasion. Although it seems that 
depth of invasion and the number of positive nodes may 
be the most important factors for AJCC stage III  disease, 
we thought that it was fascinating that in our trial there 
were trends that showed the importance of sex, age, and 
clinical and pathologic stage. 
Lastly,  it is important to note that our trial was severely 
limited by regulatory conditions placed on it by the FDA. 
As is well known, this randomized, prospective trial in 
which a new adjuvant therapy was tested in a surgical 
adjuvant study in a human tumor model that had no other 
adjuvant therapy at the time of trial development should 
have been designed with a no-treatment arm. However ,  
the FDA refused to allow us to have a no-treatment arm 
in this AJCC Stage III  melanoma randomized trial. As a 
result, we were forced to use one of the components of 
the vaccine, vaccinia virus, as the placebo. Interestingly, 
this arm in and of itself may have had some activity, and 
as a result, we cannot really compare our results cur- 
rently with those of  other trials that used a no-treatment 
arm. 
Therefore, there is work yet to be done. Although it 
took 20 years to complete this trial for the first generation 
VMO, we do plan to design another trial with a second 
generation vaccine. Moreover,  we do hope to benefit 
from what we learned in our first trial, and we can only 
benefit from these data if, and only if, the work continues 
to be reviewed and published in appropriate journals.  
Marc K. Wallack, MD 
Professor and Chairman 
Department of Surgery 
Muthukumaran Sivanandham, PhD 
Director 
Surgical Research Laboratory 
Saint Vincents Hospital 
and Medical Center 
New York, New York 
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